Combination chemotherapy with targeted therapy versus chemotherapy alone in second-line nonsmall cell lung cancer
| First author, year [ref.] | Phase | Patients | Arms | PFS months | p-value | OS months | p-value | Response rate % | p-value |
| Lee, 2013 [34] | II | 240 | Pemetrexed + erlotinib | 7.4 | 20.5 | 44.7 | |||
| Erlotinib | 3.8 | 0.002 | 22.8 | 0.747 | 29.3 | 0.031 | |||
| Pemetrexed | 4.4 | 0.005 | 17.7 | 0.168 | 10.0 | <0.001 | |||
| Dittrich, 2014 [35] | II | 165 | Pemetrexed + erlotinib | 3.19 | 0.0047 | 11.8 | 0.019 | 17.1 | 0.180 |
| Pemetrexed | 2.89 | 7.75 | 10.8 | ||||||
| Hanna, 2013 [55] | III | 713 | Pemetrexed + nintedanib | 4.4 | 0.0435 | 12.2 | 9.1 | ||
| Pemetrexed + placebo | 3.6 | 12.8 | 8.3 | ||||||
| de Boer, 2011 [51] | III | 534 | Pemetrexed + vandetanib | 4.4 | 0.108 | 9.2 | 0.219 | 19.1 | <0.001 |
| Pemetrexed + placebo | 2.9 | 10.5 | 7.9 | ||||||
| Kim, 2013 [36] | III | 938 | Pemetrexed + cetuximab | 2.9 | 0.76 | 6.9 | 0.86 | 7 | 0.20 |
| Pemetrexed | 2.8 | 7.8 | 4 | ||||||
| Docetaxel + cetuximab | 2.4 | 0.39 | 5.8 | 0.31 | 8 | 0.68 | |||
| Docetaxel | 1.5 | 8.2 | 7 | ||||||
| Schiller, 2010 [39] | II | 148 | Pemetrexed + matuzumab LD | 2.3 | 12.4 | 16 | |||
| Pemetrexed + matuzumab HD | 2.5 | 5.9 | 2 | ||||||
| Pemetrexed | 2.7 | 7.9 | 4 | ||||||
| Chiappori, 2010 [57] | II | 160 | Pemetrexed + enzastaurin | 3.0 | 0.544 | 9.6 | 0.171 | 3.9 | |
| Pemetrexed + placebo | 3.0 | 7.4 | 2.6 | ||||||
| Jänne, 2013 [44] | II | 87 | Docetaxel + selumetinib | 5.3 | 0.014 | 9.4 | 0.21 | 37.2 | <0.001 |
| Docetaxel + placebo | 2.1 | 5.2 | 0 | ||||||
| Ramlau, 2012 [49] | III | 913 | Docetaxel + aflibercept | 5.2 | 0.0035 | 10.1 | 0.90 | 23.3 | <0.001 |
| Docetaxel + placebo | 4.1 | 10.4 | 8.9 | ||||||
| Herbst, 2010 [52] | III | 1391 | Docetaxel + vandetanib | 4.0 | <0.0001 | 10.3 | 0.371 | 17 | 0.0001 |
| Docetaxel + placebo | 3.2 | 9.9 | 10 | ||||||
| Reck, 2014 [56] | III | 1314 | Docetaxel + nintedanib | 3.4 | 0.0019 | 10.1 | 0.2720 | 4.4 | 0.3067 |
| Docetaxel + placebo | 2.7 | 9.1 | 3.3 | ||||||
| Garon, 2014 [50] | III | 1253 | Docetaxel + ramucirumab | 4.5 | <0.0001 | 10.5 | 0.023 | 23 | <0.0001 |
| Docetaxel + placebo | 3.0 | 9.1 | 14 | ||||||
| Herbst, 2007 [47] | II | 120 | Docetaxel/pemetrexed + bevacizumab | 4.8 | 12.6 | 12.5 | |||
| Erlotinib + bevacizumab | 4.4 | 13.7 | 17.9 | ||||||
| Docetaxel/pemetrexed | 3.0 | 8.6 | 12.2 |
Data are presented as n, unless otherwise stated. PFS: progression-free survival; OS: overall survival; LD: low dose; HD: high dose.